Cover Image
市場調查報告書

粘膜炎:開發中產品分析

Mucositis - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 192711
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
粘膜炎:開發中產品分析 Mucositis - Pipeline Review, H1 2014
出版日期: 2014年03月31日 內容資訊: 英文 46 Pages
簡介

所謂粘膜炎是粘膜表面疼痛和發炎的疾病。常見的症狀有腹瀉、肛門和直腸的潰瘍、腹痛、吞嚥困難(吞嚥障礙)、嘔吐(噁心)、膨脹感等。治療方法包含非類固醇消炎劑(NSAID)和改變生活習慣等。

本報告提供粘膜炎的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

粘膜炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Piramal Enterprises Limited
  • Avaxia Biologics, Inc.
  • Tosk, Inc.
  • Rottapharm¦Madaus
  • SciDose LLC

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • P-276
  • CR-3294
  • TK-112690
  • Small Molecule For Mucositis
  • Melatonin
  • AVX-470

開發中產品的最新趨勢

暫停的計劃

中止開發的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4778IDB

Global Markets Direct's, 'Mucositis - Pipeline Review, H1 2014', provides an overview of the Mucositis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucositis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mucositis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Mucositis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Mucositis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Mucositis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Mucositis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mucositis Overview
  • Therapeutics Development
    • Pipeline Products for Mucositis - Overview
    • Pipeline Products for Mucositis - Comparative Analysis
  • Mucositis - Therapeutics under Development by Companies
  • Mucositis - Therapeutics under Investigation by Universities/Institutes
  • Mucositis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Mucositis - Products under Development by Companies
  • Mucositis - Products under Investigation by Universities/Institutes
  • Mucositis - Companies Involved in Therapeutics Development
    • Piramal Enterprises Limited
    • Avaxia Biologics, Inc.
    • Tosk, Inc.
    • Rottapharm|Madaus
    • SciDose LLC
  • Mucositis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • P-276 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-3294 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TK-112690 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule For Mucositis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Melatonin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AVX-470 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mucositis - Recent Pipeline Updates
  • Mucositis - Dormant Projects
  • Mucositis - Discontinued Products
  • Mucositis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 06, 2012: Research Shows Rapamycin Could Protect Against Sore Mouth After Radiotherapy
      • Aug 02, 2011: Access Pharmaceuticals MuGard Added To Humana's Pharmacy Drug Benefit Network
      • Jul 13, 2011: BioAlliance Announces Validation Of Orphan Drug Designation Application For Clonidine Lauriad
      • Jun 24, 2011: BioAlliance Pharma Submits Application For Orphan Medicinal Product Designation For Clonidine Lauriad In Europe And US
      • Jun 04, 2011: SciClone's SCV-07 Demonstrates Antitumor Activity In Various Cancer Xenograft Studies In Mice
      • May 18, 2011: SciClone To Present New Preclinical Data On SCV-07 At 2011 ASCO Annual Meeting
      • Feb 09, 2011: Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential
      • Mar 31, 2010: PolyMedix Completes Phase IB Clinical Study With Antibiotic PMX-30063
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mucositis, H1 2014
  • Number of Products under Development for Mucositis - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Mucositis - Pipeline by Piramal Enterprises Limited, H1 2014
  • Mucositis - Pipeline by Avaxia Biologics, Inc., H1 2014
  • Mucositis - Pipeline by Tosk, Inc., H1 2014
  • Mucositis - Pipeline by Rottapharm|Madaus, H1 2014
  • Mucositis - Pipeline by SciDose LLC, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Mucositis Therapeutics - Recent Pipeline Updates, H1 2014
  • Mucositis - Dormant Projects, H1 2014
  • Mucositis - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Mucositis, H1 2014
  • Number of Products under Development for Mucositis - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top